
Ţ	Unapproved Abbreviations: U, IU, Q.D., o	r Q.O.D.	Lack of lea	ding zero (i.e1 mg)	MS, MSO4, MGSO4	Trailing zero (i.e. 1.0 mg)				
$\left<\right>$	CHEMOTHERAPY ORDERS									
Ch	Only those items I will be carried out Page 1 of 3 Chemotherapy Start Date: Diagnosis: Cycle #: Freq:									
	Obtain the following, prior to chemotherapy:	Diagnosis:	Use Lat	o results from /	,	Freq: acy may order lab pertinent to				
Lab	CBC with differential CMP BMP Notify provider EKG MUGA prior to adminis Qual. BHcg Patient/caregiv Other:	stration er education	(At leas WBC Plt SCr Other	t 72 hrs prior to chemo ANC T. Bili CrCl) dosing Calvert Target ────────────────────────────────────	method for Carboplatin dosing: AUC X (CrCl + 25) = Dose in mg				
	Height Actual Weight Treatme (in) (kg)	ent BSA	(m^2) \square	emotherapy dose base Actual Body WT	ed on:	Adjusted Body WT				
Hydration	IV Maintenance Fluids: Pre-hydration: Post-hydration: Hold chemo and call MD if ANC < 1.5 or Other			Hold for for	hydration during chemothe hours; Prior to hours; Prior to	Total bilirubin > 1.5 or				
	Chemo Drug (generic name) (See page 2 for antiemetics)		se/m² Dose/kg	Treatment Dose (mg or Units)	Route & Infusion Duration	Frequency/number of doses or days				
						☐ day 1 only ☐ day 2 only ☐ days ☐ other				
						□ day 1 only □ day 2 only □ days				
apy						□ day 1 only □ day 2 only □ days				
nunotherapy						I □ days				
						□ other □ day 1 only □ day 2 only □ days □ other				
Chemotherapy / Imi						☐ day 1 only ☐ day 2 only ☐ days ☐ other				
Chem						☐ day 1 only ☐ day 2 only ☐ days ☐ other				
	* Pharmacy to use standard dilution/volume un		e specified							
	Additional Orders: (see page 2 for ANTIEMETICS)									
	ate: Time:	Physician Sig	gnature: <u>X</u>							
(WedicalCity 3901 West 15th Street Plano, Texas 75075 Plano, Texas 75075 Plano, Texas 75075 Plano P									

Unapproved Abbrevia		or Q.O.D. Lack of leading	zero (i.e. 1 ma)	MS, MSO4, MGSO4	Trailing zero (i.e. 1.0 mg)
Tonapproved Abbrevia			zero (i.e i ilig)	M3, M304, M3304	
<u> </u>		CHEMOTHERA			
		Only those items			Page 2 of 3
		Chemotherapy (Administe	-		**Pharmacy will mix Zofran and
		□ orally OR □ IVPB on day(mg □ orally OR □ IV		-	Decardron in the same 0.9% Sodium Chloride 50 mL IVPB to
☐ **Dexamethasone (De			PB 011 days(s)		be infused over 15 min
		nd 3	end) 125 mg orally (on day 1 (HIGHI Y EME	
,		ly or \Box IVP every 6 hours on	, ,		,
□ Other	-				
LOW Emetogenic Ch	emotherapy (Admir	nister 30 - 60 min prior to c	hemotherapy)		
Dexamethasone (Dec		-	.,,		
Lorazepam (Ativan)					
For BREAKTHROUGH	I Nausea/Vomiting				
Sequencing:					
		ng orally / IVP every 6 hours PR 6 hours PRN breakthrough nau	-	-	
		VP every 12 hours PRN breakth			
	. , -	VPB every 6 hours PRN breakth	•	-	
		4 hours PRN breakthrough nat	-	-	
		-	-		PRN breakthrough nausea and/or
vomiting					
Scopolamine	(Transderm Scop) 1.5	mg patch transdermally every 7	2 hours		
Date:	Time:	Physician Signature: X			
	-	2001 Wast 15th Streat	PATIENT IDENTIFICAT	ΓΙΟΝ	/
(Medica	lCity	3901 West 15th Street Plano, Texas 75075			
Plano	e'	(972) 596-6800			
CHEM	IOTHERAPY (ORDERS			
│ 		PPO-698B (Rev. 06/17)			Page 2 of

					ORDERS		Page 3 of 3
		2011 Emetic Risk				Intravenously	-
High (>90%) Moderate (30%-90%)					Low (10%-30	Minimal (<10%)	
Carmustine Cisplatin Cyclophosphamide >1500 mg/m2 Dacarbazine Dactinomycin Mechlorethamine Streptozotocin		Azacitidine Alemtuzumab Bendamustine Carboplatin Cyclophosphamide < 1500 mg/m2 Cytarabine > 1000 mg/m2 Daunorubicin* Doxorubicin* Epirubicin*	Idarubicin* Ifosfamide Irinotecan Oxaliplatin	Docetaxe Doxorubic Etoposide Gemcitab Ixabepilor Methotrex	ib eel omab < 1000 mg/m2 l in liposome ine ne ate	Mitomycin Mitoxantrone Paclitaxel Panitumumab Pemetrexed Temsirolimus Topotecan Trastuzumab	2-Chlorodexyadenosine Bevacizumab Bleomycin Busulfan Cetuximab Fludarabine Pralatrexate Rituximab Vinblastine Vincristine Vinorelbine
		combined with cyclophospł Clinical Oncology	namide, are now	designated as	s high emetic risk		
		<u>.</u>	CO Guideline	Update a	nd Recommend	lations	
		2006			2011		
Highly emetogenic Moderately emetogenic	dexamethase patients rece risk, the two- is recomment the combinate dexamethase The three-dr dexamethase receiving AC	ug combination of a 5-HT3 one, and aprepitant before eiving cisplatin and all other drug combination of dexar ided. The Update Commit tion of a 5-HT3 serotonin re one on days 2 and 3. ug combination of a 5-HT3 one, and aprepitant is reco there there there are a common to the second there there are a common to the second there are a common to the second to the second there are a common to the second to the second to the second there are a common to the second to the second to the second to the second there are a common to the second to	chemotherapy. r agents of high e nethasone and a tee no longer rec eceptor antagonis receptor antagon mmended for pat	In all emetic prepitant ommends st and nist, tients noderate	The 3-drug combination of an NK1 receptor antagonist (days 1-3 for aprepitant; day 1 only for fosaprepitant), a 5-HT3 receptor antagonist (day 1 only), and dexamethasone (days 1-3 or 1-4) is recommended for patients receiving highly emetogenic chemotherapy. This recommendation is unchanged since the 2006 update, but reworded for clarification. The Update Committee also recommended reclassification of the combined AC regimen as highly emetogenic. The 2-drug combination of palonosetron (day 1 only) and dexamethasone (days 1-3) is recommended for patients receiving moderately emetogenic chemotherapy. If palonosetron is not available,		
	emetic risk other than AC, we recommend the two-drug combination of a 5-HT3 receptor antagonist and dexamethasone. In patients receiving AC, aprepitant as a single agent is recommended on days 2 and 3. For all other chemotherapies of moderate emetic risk, single agent dexamethasone or a 5-HT3 receptor antagonist is suggested for the prevention of emesis on days 2 and 3.				clinicians may substitute a first-generation 5-HT3 serotonin receptor antagonist, preferably granisetron or ondansetron.		
		one 8 mg is suggested. No routine preventative ed emesis is suggested.			No change since 2006		
		om the original guideline. No antimetic should be routinely before or after.			No change since 2006		
Combination chemotherapyNo change from the original guideline. Use appropriate agent for the greatest emetic risk.			No change. Anthracycline + cyclophosphamide (AC) are now classified as highly emetogenic.				
Useful Calculations Body surface area, BSA (m ²) = square root of [HT (in) x WT (lb) / 3131] OR square root of [(HT (cm) x WT (kg)) / 3600] Ideal body weight, IBW (male) = 50 + (2.3 x HT in inches above 5ft). IBW (female) = 45.5 + (2.3 x HT in inches above 5ft) Adjusted body weight (ABW) = IBW + 0.4 (actual weight-IBW). ABW usually used when actual weight is > 30% of IBW Creatinine Clearance, CrCl (ml/min) = [140-age) x IBW (kg)]/72 x SCr. Multiply X 0.85 for females Absolute Neutrophil Count, ANC = (segs + bands)/100 x WBC in thousands OR (segs + bands)/100 x WBC Carboplatin Dosing, Total Dose (mg) = Target AUC X (CrCl + 25).							
Date:	Tin	ne: Physic	cian Signature:	x			
					FIENT IDENTIFICATION		



PATIENT IDENTIFICATION

CHEMOTHERAPY ORDERS

